Cairo – Mubasher: The Russian Direct Investment Fund (RDIF) signed an agreement with Egypt’s Minapharm Pharmaceuticals and its Berlin-based subsidiary ProBioGen AG to manufacture more than 40 million doses annually of the Russian vaccine against coronavirus (COVID-19), Sputnik V.
The vaccine will be produced at Minapharm’s Cairo-based biotech facility to be distributed globally, Russia’s sovereign wealth fund said in a statement on Thursday.
The release of the vaccine is forecast to take place in the third quarter (Q3) of 2021.
The Russian vaccine, which has been approved for use in 61 countries, has shown an efficacy rate of 97.6%.
On Wednesday, Egypt’s Prime Minister, Mostafa Madbouly, witnessed the signing of two agreements between the Egyptian Holding Company for Biopharmaceuticals and Vaccines (Vacsera) and China’s Sinovac Life Sciences Company to manufacture the Sinovac vaccine in Egypt.
